7 completed. 4 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 2 | Completed 2 |
Follow Light Sciences Oncology: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia talaporfin sodium, Saline, Drug Activator 100 J/cm - Benign Prostatic Hyperplasia | Phase 2 | Completed | Light Sciences Oncology | 225 | 2014-11-01 | 2018-08-08 |
| Study of Light-Activated Talaporfin Sodium in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) talaporfin sodium, Transurethral illumination with light emitting diodes, Placement - Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms | Phase 2 | Completed | Light Sciences Oncology | 21 | 2009-05-01 | 2012-11-16 |
| Phase 1 Study of the Litx™ BPH System in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) Talaporfin sodium, Placement of device in prostate urethra, Transurethral illumination with light emitting diodes (Litx™ BPH Device) - Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms | Phase 1 | Completed | Light Sciences Oncology | 12 | 2008-06-01 | 2012-11-16 |
| Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases Talaporfin sodium, Percutaneous placement of device in liver metastases, Interstitial light emitting diodes - Liver Metastases, Colorectal Neoplasms | Phase 3 | Completed | Light Sciences Oncology | 483 | 2007-02-01 | 2015-08-25 |
| Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma LS11 (talaporfin sodium), Light source (interstitial light emitting diodes), Intraoperative placement of device in glioma - Glioma, Glioblastoma Multiforme | Phase 2 | Completed | Light Sciences Oncology | 18 | 2006-11-01 | 2012-11-16 |
| A Phase 3 Study of Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC) Talaporfin sodium, Interstitial Light Emitting Diodes, Percutaneous placement of device in the liver - Carcinoma, Hepatocellular, Liver Neoplasms | Phase 3 | Completed | Light Sciences Oncology | 208 | 2006-07-01 | 2015-01-30 |
| Tumor Ablation With Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC) Photodynamic therapy, Talaporfin Sodium - Carcinoma, Hepatocellular, Liver Neoplasms | Phase 1 / Phase 2 | Completed | Light Sciences Oncology | 25 | 2005-04-01 | 2007-12-07 |
Liver Neoplasms (3) · Prostatic Hyperplasia (3) · Carcinoma, Hepatocellular (2) · Lower Urinary Tract Symptoms (2) · Astrocytoma (1) · Colorectal Neoplasms (1) · Glioblastoma (1) · Glioma (1) · Neoplasm Metastasis (1) · Neoplasm Recurrence, Local (1)
Talaporfin (7) · Drug Implants (1) · Embryo Implantation (1) · Folfox protocol (1) · Photochemotherapy (1) · Sodium Chloride (1) · Standard of Care (1)
Serbia (3) · Croatia (2) · Hong Kong (2) · India (2) · Poland (2) · Singapore (2) · Sweden (2) · United States (2) · Australia (1) · Austria (1) · Bosnia and Herzegovina (1) · Germany (1) · Italy (1) · Latvia (1) · Malaysia (1)
Sy-Shi Wang, PhD (6) · Lisa Koch-Hulle (1)